Eisai Co Ltd $ 67.00 0 (0%)
ESALF News and Headlines - Eisai Co Ltd
Growth-focused investors may want to consider the following stocks since their price-earnings without non-recurring items ratios stand below 20 and their trailing 12-month earnings per share have grown significantly over the past year.
The first company that qualifies is Eisai Co. Ltd. (ESALY), a Japanese drug manufacturer focusing on the development of treatments for Alzheimer's disease, dementia, insomnia and several neurological conditions. The company is also producing painkillers, anticancer therapies and treatments for gastrointestinal affections and autoimmune diseases.
The trailing 12-month net earnings increased by approximately 102% to 424.80 Japanese yen ($4.04) per diluted share as
Analysts have suggested that an approved disease-modifying treatment for Alzheimer's could be worth more than $10 billion to the company that comes up with it. So far, the pot of gold at the end of the rainbow has been just an illusion.
To date, more than 200 testing programs focused on the physical changes in the brains of Alzheimer's patients have failed to yield a single treatment, according to FierceBiotech. Billions of dollars have been spent to unlock the mystery of Alzheimer's and to find a therapy that works against the underlying cause of the disease to no avail.
Already on the ropes after a recent patent ruling went against it, Biogen Inc. (BIIB) stock could be down for the count if the company's Alzheimer's drug fails to gain approval. Based on what analysts are saying, the odds of that happening appear to be about 50-50.
Shares of the Cambridge, Massachusetts-based biotech traded as high as $295 earlier in the week, but are down about 6% following news that the British generics specialist Mylan (MYL) had received Food and Drug Administration approval to launch its new Multiple Sclerosis drug.
What's problematic for Biogen is that
Among the largest publicly traded pharmaceutical companies, Novo Nordisk (NVO) and Roche (RHHBY) had the highest returns on invested capital during the period from 2011 to 2019, according to a report from the Westhealth Policy Center. At the other end of the spectrum were Abbott Laboratories (ABT) and Easai Co. (TSE:4523).
In simplest terms, ROIC is a profitability ratio that indicates just how efficient a company is turning capital into profit. It measures the return that an investment generates for those who have provided capital (i.e., bondholders and stockholders).
ROIC can be important to investors because it is a key
The need for Biogen Inc. (BIIB) to get its Alzheimer’s drug approved became more urgent this week after the company lost a patent dispute over its top-selling medication.
A West Virginia District Court ruled that a key patent covering Biogen's multiple sclerosis medicine Tecfidera is invalid, a win for the generics company Mylan (MYL), which could have a copycat on the market as early as next year, according to an article in BioPharma Dive.
The disappointing news shaved about $25 off Biogen’s share price this week, but the stock did bounce back, gaining more than $10 on Friday to close
Joel Greenblatt (Trades, Portfolio) introduced the individual investing world to the “Magic Formula” when he published his 2005 book, “The Little Book That Beats the Market.” The idea behind the Magic Formula is to apply a simple mathematical formula to find good businesses trading at bargain prices.
The formula ranks companies based on the combination of two metrics: earnings yield and return on capital. As the formula works best when applied to U.S. companies and companies with market caps of at least $100 million, it also eliminates companies that do not meet these criteria, as small-cap and
It’s trick-or-treat time, and an individual who claims to be a former member of Biogen’s (BIIB) research and development team thinks investors who helped push the stock up 30% in the past week on news the company’s experimental drug for Alzheimer’s has been resurrected may be left holding the bag.
In an Oct. 28 opinion piece in STAT, Ted Whitford, who wrote he “worked on and around” the drug aducanumab for years," thinks the company may just be “spinning bad data.” A request to Biogen to verify Whitford’s statements went unanswered.
As Margaret Moran reported in an Oct. 25
This past Tuesday, Biogen Inc. (BIIB) announced it has changed its outlook regarding its trial-phase Alzheimer’s drug aducanumab in light of new test results.
Biogen is a pharmaceutical company that develops treatments for neurological and neurodegenerative diseases. In March, Biogen and Eisai Co. Ltd.(TSE:4523), which it is collaborating with for the aducanumab project, decided to abandon the drug during phase 3 testing. The decision came after a futility analysis conducted on previous phase 1/1b trials from before Dec. 26, 2018, which concluded that, based on the 1,748 patients who had completed the 18-month trial period at the time, later trials
The Vanguard Health Care Fund (Trades, Portfolio) disclosed this week its top five buys for the first quarter included a new position in Galapagos NV (GLPG) and position boosts of the following four companies: Elanco Animal Health Inc. (ELAN), Teva Pharmaceuticals Industries Ltd. (TEVA), Centene Corp. (CNC) and Eisai Co. Ltd. (TSE:4523).
Managed by Jean Hynes, the fund seeks long-term capital appreciation through investments in domestic and foreign companies in various industries within the health care sector. As of quarter-end, the 89-stock equity portfolio contains 97.65% exposure to health care, with a buy impact of 3.25% and
It’s generally accepted that health care is considered one of the top defensive sectors. Given the market’s recent gyrations, it may make sense for investors concerned that the market is on shaky ground to consider shifting some of their assets into the industry.
Of course, past performance is no guarantee of future returns, but it’s worthwhile to look at some of the companies that have outperformed the market since the crash of September 2008.
One large-cap stock that stands out is UnitedHealth Group (UNH). Investors who had the foresight to put their money into this Minnesota-based insurer more than 10
Biotechnology is considered one of the most dynamic and profitable sectors, where investment in research and development is necessary for survival. Biogen Inc. (BIIB) is one of the leading players in this sector, with a proven track record in neurological and neurodegenerative diseases.
The company has a strong portfolio of drugs catering to diseases like multiple sclerosis, Alzheimer’s, dementia and neuromuscular disorders. Some of its key drugs include Tecfidera, Avonex, Plegridy, Fumaderm, Gazyva and Spinraza, Biogen’s top-performing drug, which treats spinal muscular atrophy.
Apart from the revenues generated from these drugs, Biogen has key partnerships with other large pharmaceutical giants,
On July 5, Biogen (BIIB) and Eisai (ESALY) announced positive topline results of BAN2401, a drug candidate for the treatment of Alzheimer's disease. This is significant because it further secures Biogen’s dominance in the Alzheimer's disease space.
Currently, Biogen has six drug candidates in development for the treatment of Alzheimer's disease, two of which are in phase 3 clinical trials with completion dates estimated around 2020. In a previous article, I noted that Aducanumab (also developed by Biogen) was arguably the most promising Alzheimer’s disease drug candidate in development and
The market was singing Biogen Inc.’s (BIIB) praises on Friday after the company released favorable results from a phase II trial of its Alzheimer’s drug on Thursday.
In a partnership with Japanese pharmaceutical company Eisai Co. Ltd. (TSE:4523), the Cambridge, Massachusetts-based biotech company treated 856 patients who had early-stage Alzheimer’s disease with varying dosages of BAN2401.
According to the company, BAN2401 is an anti-amyloid beta protofibril antibody that selectively binds to and eliminates amyloid beta aggregates, which are believed to contribute to neurodegeneration, in the brain.
After 18 months, the study found the patients who were treated with the
Jean Hynes of the Vanguard Health Care Fund (Trades, Portfolio) added 1,094,126 shares to the stake in Eisai (TSE:4523)Â during the second quarter. The trade had a 0.13% impact on the portfolio. Vanguard now owns 14,033,001 shares in the company.
Headquartered in Tokyo and established in 1941, Eisai is an international pharmaceutical company that produces and manufactures prescription medicines and over-the-counter products. The company has manufacturing sites in Japan, North Carolina, Maryland, Bogor (Indonesia), Suzhou (China), Tainan (Taiwan) and Visakhapatnam (India) as well as Hatfield and Hertfordshire in
|2020-11-06 $ 74.75 (%)|
|2020-05-13 $ 62 (-17.88%)|